ArticleDNA research : an international journal for rapid publication of reports on genes and genomes2017
Sequencing and phasing cancer mutations in lung cancers using a long-read portable sequencer.
Article in DNA research : an international journal for rapid publication of reports on genes and genomes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- A Hitchhiker's Guide to long-read genomic analysis.Genome research · 2025Review
- The Road Toward Nanopore Sequencing of Glycosaminoglycans.Handbook of experimental pharmacology · 2025Review
- The Application of Long-Read Sequencing to Cancer.Cancers · 2024Review
- Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing.EMBO molecular medicine · 2023Article
- Transcript capture and ultradeep long-read RNA sequencing (CAPLRseq) to diagnose HNPCC/Lynch syndrome.Journal of medical genetics · 2023Article
- Transcriptome profiling for precision cancer medicine using shallow nanopore cDNA sequencing.Scientific reports · 2023Article
- Large-Scale Complete Sequencing and Haplotyping of 1-10 kb DNA Molecules Using Short Massively Parallel Reads.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Editorial: Applications of RNA-seq in cancer and tumor research.Frontiers in genetics · 2023Article
- From Samples to Germline and Somatic Sequence Variation: A Focus on Next-Generation Sequencing in Melanoma Research.Life (Basel, Switzerland) · 2022Review
- Transposon activity, local duplications and propagation of structural variants across haplotypes drive the evolution of the Drosophila S2 cell line.BMC genomics · 2022Article
- Focus on using nanopore technology for societal health, environmental, and energy challenges.Nano research · 2022Review
- Application of third-generation sequencing in cancer research.Medical review (2021) · 2021Article
- Nanopore sequencing technology, bioinformatics and applications.Nature biotechnology · 2021Review
- DNA methylation-calling tools for Oxford Nanopore sequencing: a survey and human epigenome-wide evaluation.Genome biology · 2021Article
- Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection.Genome biology · 2021Article
- Full-length transcriptome analysis reveals the mechanism of acupuncture at PC6 improves cardiac function in myocardial ischemia model.Chinese medicine · 2021Article
- Nanopore Technology and Its Applications in Gene Sequencing.Biosensors · 2021Review
- Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer.Genome biology · 2021Article
- Long-read sequencing for non-small-cell lung cancer genomes.Genome research · 2020Article
- Nanopore Sequencing in Blood Diseases: A Wide Range of Opportunities.Frontiers in genetics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here, we employed cDNA amplicon sequencing using a long-read portable sequencer, MinION, to characterize various types of mutations in cancer-related genes, namely, EGFR, KRAS, NRAS and NF1. For homozygous SNVs, the precision and recall rates were 87.5% and 91.3%, respectively. For previously reported hotspot mutations, the precision and recall rates reached 100%. The precise junctions of EML4-ALK, CCDC6-RET and five other gene fusions were also detected. Taking advantages of long-read sequencing, we conducted phasing of EGFR mutations and elucidated the mutational allelic backgrounds of anti-tumor drug-sensitive and resistant mutations, which could provide useful information for selecting therapeutic approaches. In the H1975 cells, 72% of the reads harbored both L858R and T790M mutations, and 22% of the reads harbored neither mutation. To ensure that the clinical requirements can be met in potentially low cancer cell populations, we further conducted a serial dilution analysis of the template for EGFR mutations. Several percent of the mutant alleles could be detected depending on the yield and quality of the sequencing data. Finally, we characterized the mutation genotypes in eight clinical samples. This method could be a convenient long-read sequencing-based analytical approach and thus may change the current approaches used for cancer genome sequencing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.